	ltem	Guidance for Reporting	Reported in section
TITLE	·		
Title	1	Identify the study as an economic evaluation and specify the interventions being compared.	page 1
ABSTRACT			
Abstract	2	Provide a structured summary that highlights context, key methods, results and alternative analyses.	page 2
INTRODUCTION			
Background and objectives	3	Give the context for the study, the study question and its practical relevance for decision making in policy or practice.	page 5–6
MÉTHODS			
Health economic analysis plan	4	Indicate whether a health economic analysis plan was developed and where available.	supplementary material page 29
Study population	5	Describe characteristics of the study population (such as age range, demographics, socioeconomic, or clinical characteristics).	page 7
Setting and location	6	Provide relevant contextual information that may influence findings.	page 7
Comparators	7	Describe the interventions or strategies being compared and why chosen.	page 8–9
Perspective	8	State the perspective(s) adopted by the study and why chosen.	page 9
Time horizon	9	State the time horizon for the study and why appropriate.	page 9
Discount rate		Report the discount rate(s) and reason chosen.	page 8
Selection of outcomes	11	Describe what outcomes were used as the measure(s) of benefit(s) and harm(s).	page 9
Measurement of outcomes	12	Describe how outcomes used to capture benefit(s) and harm(s) were measured.	page 9
Valuation of outcomes	13	Describe the population and methods used to measure and value outcomes.	page 8–9
Measurement and valuation of resources and costs	14	Describe how costs were valued.	page 9, suppleme material page 29-
Currency, price date, and conversion	15	Report the dates of the estimated resource quantities and unit costs, plus the currency and year of conversion.	page 9
Rationale and description of model	16	If modelling is used, describe in detail and why used. Report if the model is publicly available and where it can be accessed.	page 18
Analytics and	17	Describe any methods for analysing or statistically transforming data, any	supplementary
assumptions		extrapolation methods, and approaches for validating any model used.	material page 29
Characterizing heterogeneity	18	Describe any methods used for estimating how the results of the study vary for sub-groups.	page 8, suppleme material page 29-
Characterizing	19	Describe how impacts are distributed across different individuals	supplementary
distributional effects Characterizing	20	or adjustments made to reflect priority populations.	material page 29 page 9, suppleme
uncertainty	20	Describe methods to characterize any sources of uncertainty in the analysis.	material page 29
Approach to engagement with patients and others affected by the study RESULTS	21	Describe any approaches to engage patients or service recipients, the general public, communities, or stakeholders (e.g., clinicians or payers) in the design of the study.	supplementary material page 29
Study parameters	22	Report all analytic inputs (e.g., values, ranges, references) including	page 8, suppleme
Summary of main	23	uncertainty or distributional assumptions. Report the mean values for the main categories of costs and outcomes of	material page 29-
results Effect of uncertainty	24	interest and summarise them in the most appropriate overall measure. Describe how uncertainty about analytic judgments, inputs, or projections affect findings. Report the effect of choice of discount rate and time horizon, if applicable.	page 12
Effect of engagement with patients and others affected by the study	25	Report on any difference patient/service recipient, general public, community, or stakeholder involvement made to the approach or findings of the study	supplementary material page 29
DISCUSSION			
Study findings, limitations, generalizability, and current knowledge	26	Report key findings, limitations, ethical or equity considerations not captured, and how these could impact patients, policy, or practice.	page 14–17
OTHER RELEVANT INFO	RMATIC	DN	1
Source of funding	27	Describe how the study was funded and any role of the funder in the identification, design, conduct, and reporting of the analysis	page 10
-		Report authors conflicts of interest according to journal or	

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. BMJ. 2022;376:e067975.

The checklist is Open Access distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.